Skip to main content

Peer Review reports

From: A phase II study of first-line afatinib for patients aged ≥75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027

Original Submission
24 Jun 2020 Submitted Original manuscript
2 Jul 2020 Reviewed Reviewer Report
10 Jul 2020 Reviewed Reviewer Report - Joseph Abi Jaoude
17 Jul 2020 Reviewed Reviewer Report - Junaid Ahmed
18 Jul 2020 Reviewed Reviewer Report
22 Jul 2020 Reviewed Reviewer Report
28 Jul 2020 Reviewed Reviewer Report - Markus Knott
3 Aug 2020 Reviewed Reviewer Report
7 Aug 2020 Reviewed Reviewer Report
26 Nov 2020 Author responded Author comments - Yuji Minegishi
Resubmission - Version 2
26 Nov 2020 Submitted Manuscript version 2
29 Nov 2020 Reviewed Reviewer Report - Joseph Abi Jaoude
8 Dec 2020 Reviewed Reviewer Report
20 Dec 2020 Reviewed Reviewer Report
21 Dec 2020 Reviewed Reviewer Report
28 Jan 2021 Author responded Author comments - Yuji Minegishi
Resubmission - Version 3
28 Jan 2021 Submitted Manuscript version 3
Publishing
31 Jan 2021 Editorially accepted
1 Mar 2021 Article published 10.1186/s12885-021-07861-1

You can find further information about peer review here.

Back to article page